Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> USA300

Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> USA300

<b>Background/Objectives</b>: Community-acquired methicillin-resistant <i>Staphylococcus aureus</i> (CA-MRSA) greatly complicates the treatment of skin and soft tissue infections (SSTI). It was previously found that subcutaneous (SQ) treatment with the mononuclear phagocyte (...

Full description

Saved in:
Bibliographic Details
Main Authors: Jason P. Stewart, Caleb M. Sandall, Jacob E. Parriott, Stephen M. Curran, Russell J. McCulloh, Donald R. Ronning, Joy A. Phillips, Robin Schroeder, Christy Neel, Kelly F. Lechtenberg, Samuel M. Cohen, Yazen Alnouti, Sohel Daria, D. David Smith, Joseph A. Vetro
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceutics
Subjects:
antimicrobial resistance
AMR
antibiotic resistance
ABR
drug-resistant bacteria
antibiotic-resistant bacteria
Online Access:https://www.mdpi.com/1999-4923/16/12/1621
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/16/12/1621

Similar Items